ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Rang in aandelen
#19092
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Aandeelprijs
$0.38168475
Marktkapitalisatie
$159.94M
Verandering (1 dag)
-4.31%
Verandering (1 jaar)
-70.34%
Land
CN
Handel ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Categorie
Healthcare
Koersgeschiedenis voor ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Hoogste slotkoers: $0.40 op 2026-10-01
Laagste slotkoers: $3.27 op 2023-09-01
Laagste slotkoers: $3.27 op 2023-09-01
Koersgeschiedenis van ImmuneOnco Biopharmaceuticals (Shanghai) Inc. van 2023 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -25.34% |
| 2025 | 11.64% |
| 2024 | -80.79% |
| 2023 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
